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ABSTRACT 
Grip strength has been identified as a valid predictor of frailty and disability and has 
been shown to be a cost-effective method to assess muscular strength in older 
populations.  Grip strength is also used in working definitions for sarcopenia 
classification.  However, various forms of arthritis have been shown to negatively 
impact grip strength scores, which could potentially lead to misclassification.  
Therefore, the aim of this study was to investigate if hand arthritis is related to 
sarcopenia classification in a group of older women with or without symptoms of 
sarcopenia and if arthritis is related to upper and lower body muscular strength.  
Sarcopenia status was based on established working definitions that use grip strength 
or chair stands, physical function, body composition measures in a sample of 61 
(71.9±4.6) and a sub-sample of 25 (72.3±4.6 years) older women.  Arthritis status was 
based on self-report and grip strength was measured using a hand dynamometer.  
Upper body muscular strength was assessed with a one repetition maximum (1RM) 
test on a chest press machine, while lower body muscular strength was assessed with a 
1RM test on a leg press machine.  Characteristics of both samples were expressed as 
mean±SD and frequencies.  A Fisher’s exact test assessed the relationship between 
non-specific arthritis and hand arthritis to sarcopenia status.  Pearson’s correlation 
coefficients were used to assess the strength of the relationship between grip strength, 
chest press 1RM (CP1RM), and leg press 1RM (LP1RM) in those with hand arthritis 
and non-specific arthritis.  Non-specific arthritis and hand arthritis were not related to 
sarcopenia status (p=0.36, p=0.44).  There was no relationship between grip strength 
and CP1RM, grip strength and LP1RM, and CP1RM and LP1RM for those with non-
  
specific arthritis or hand arthritis.  Although non-specific arthritis and hand arthritis 
were not related to sarcopenia status via grip strength or failure to complete a single 
chair stand in this sample, studies with larger sample sizes should be done to assess 
how arthritis is related to sarcopenia status in older women and what forms are related 
to sarcopenia status.  
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PREFACE 
This thesis is written to comply with the University of Rhode Island graduate 
school manuscript format.  The thesis document contains one manuscript: Relationship 
between Arthritis and Muscular Strength in Older Women with Symptoms of 
Sarcopenia.  The manuscript has been written in a form formatted for publication in 
the Journal of Aging Research.   
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ABSTRACT  
Grip strength is identified as a cost-effective, valid measure to assess muscular 
strength in older populations and is also used in the working definitions for 
sarcopenia.  Various forms of arthritis impact grip strength scores, which could 
potentially lead to misclassification.  The aim of this study was to investigate if hand 
arthritis is related to sarcopenia classification in a group of older women with or 
without symptoms of sarcopenia and if arthritis is related to upper and lower body 
muscular strength.  Sarcopenia status was based on established working definitions 
that use grip strength or chair stands, gait speed, and body composition measures in a 
sample of 61 older women (71.9±4.6 years) screened for a randomized controlled trial 
and 25 of those 61 (72.3±4.6 years) who partook in baseline testing for that 
randomized controlled trial.  Arthritis status was based on self-report and grip strength 
was measured using a hand grip dynamometer.  Hand arthritis and non-specific 
arthritis were not related to sarcopenia status.  No relationship between grip strength 
and chest press one repetition maximum (CP1RM), grip strength and leg press one 
repetition maximum (LP1RM), or CP1RM and LP1RM was observed.  Further studies 
should address how specific forms of arthritis are related to sarcopenia status.  
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INTRODUCTION 
Sarcopenia is defined as the loss of muscular strength, functionality, and lean 
mass seen with aging [1,2] that is related to the development of functional limitations 
[3].  In the United States in 2000, the estimated health care costs of sarcopenia for 
women were $29.5 billion [4].  Sarcopenia is a public health problem that will 
continue to be an economic burden as the older population continues to increase [5]. 
Moreover, women have a greater life expectancy and are at higher risk for functional 
disability due to their quicker decline in muscular strength when compared to men [5].  
Additionally, there is currently no universally accepted sarcopenia classification 
system, but national and international organizations have established working 
classification systems that include measures of muscular strength, physical 
functioning, and lean mass [6-9].                                                                             
 While organizations have various criteria for sarcopenia, muscular strength is 
often assessed using grip strength test because it is considered a valid measure to 
predict overall muscular strength [6,10-12].  Using a hand grip dynamometer instead 
of the current gold standard, isokinetic dynamometry is easier to administer to large 
populations as it is more portable and compact than an isokinetic dynamometer [11-
13].  Additionally, grip strength is predictive of health outcomes including frailty, 
disability, and mortality since naturally, muscular strength declines with age [10,13-
18].                                                                                                                      
 However, using grip strength as a measure of muscular strength based on the 
current sarcopenia working definitions may not be the best measure when functional 
limitations such as arthritis are present.  Arthritis is a chronic disease characterized by 
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joint stiffness and inflammation, which can often result in joint deformities from 
swelling and osteophyte formation as well as decreased functionality [19-22].  In the 
United States, arthritis is the most common cause of disability and between 2013 and 
2015, approximately 54.4 million adults were diagnosed with arthritis [23].  Older 
adults account for 49.6% of the 54.4 million adults diagnosed and arthritis was more 
prevalent in women than men [24].  Arthritis also leads to pain as well as poor 
physical functioning in the affected joint(s) and can make various physical 
assessments difficult, including evaluations in grip strength [27-32] and gait speed 
[31,32].  Additionally, arthritis has been shown to be associated with decreases in lean 
mass [31,33].                                                                                                              
 There are over 100 different types of arthritic disease including osteoarthritis, 
rheumatoid arthritis, gout, and fibromyalgia [21].  Osteoarthritis and rheumatoid 
arthritis are two forms of arthritis that commonly affect the joints of the hand and are 
also some of the most common forms [24-26].  Since the older population continues to 
increase and arthritis is more prevalent with increasing age and amongst women, 
arthritis may be related to sarcopenia status.                                                                    
 A potential misclassification of sarcopenia due to arthritis, but not a lack of 
overall body strength, has not been addressed in the literature.  Therefore, the purpose 
of this study was to determine if hand arthritis is related to sarcopenia classification in 
older women with or without symptoms of sarcopenia.  A secondary aim was to assess 
if grip strength was related to measures of upper and lower body muscular strength in 
a group of older women with symptoms of sarcopenia by hand arthritis status. 
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MATERIALS AND METHODS 
Study Design 
The study utilized a cross-sectional analysis to assess the potential effects of hand 
arthritis on sarcopenia status from grip strength measurements or from failure to rise 
from a chair unassisted in 61 community-dwelling older women.  A second cross 
sectional analysis of 25 women from the 61, who partook in baseline testing for the 
10-week, University of Rhode Island Institutional Review Board approved, Resistance 
Exercise Study to Reclaim Lean Muscle and Strength (URI RESTORE ME Project 
IRB # HU1415-168) assessed grip strength in relation to upper and lower body 
muscular strength.  The 61 women were screened prior to the baseline testing session 
for potential enrollment into the URI RESTORE ME project, and of those 61, only 25 
women partook in the baseline testing for the URI RESTORE ME intervention phase.  
Participants  
This study included 61 women (71.9±4.6 years) screened as potential participants 
for the URI RESTORE ME randomized controlled trial and 25 women (72.3±4.6 
years) of those 61 who were selected for that trial and who also exhibited at least one 
symptom or sign of sarcopenia defined by various working group definitions.  These 
community-dwelling older women were recruited from southern Rhode Island via 
flyers, community talks, and word of mouth, and were initially phone screened for 
study eligibility.  The inclusion and exclusion criteria for the study are presented in 
Table 1.  Participants who initially qualified based on the inclusion and exclusion 
criteria provided written informed consent and were screened for sarcopenia using the 
European Working Group on Sarcopenia in Older People (EWGSOP), the 
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International Working Group (IWG), and the Foundation for the National Institutes of 
Health Sarcopenia Project (FNIHSP) criteria.  They were assessed on their 
performance in gait speed, grip strength, a single chair stand, height, weight, and lean 
mass measured via segmental multi-frequency bioelectrical impedance analysis (SMF-
BIA).  Based on the established criteria, 38 participants were qualified for the 
randomized controlled trial but only 25 were selected for participation into the study 
based on their pre-screening results, medical histories, and a physical activity 
readiness questionnaire (PAR-Q).  The other 13, who were eligible, were eliminated 
due to time commitment issues or orthopedic concerns. Figure 1 depicts a flow chart 
of the subject recruitment process.  
Outcome Measures 
 Sarcopenia Status: Prior to the beginning of baseline testing, participants 
completed pre-screening assessment to determine their sarcopenia status.  The 
EWGSOP [6], the IWG [7], and the FNIHSP [8,9] working definitions were applied to 
each participant to determine their sarcopenia status based on their performance in a 
hand grip strength test, a single chair stand, gait speed, and their appendicular lean 
mass measured using a segmental multi-frequency bioelectrical impedance analysis 
(InBody 570 SMF-BIA, Biospace Co, Ltd, Korea) device.  The following cut-points 
were used: <20 kg for grip strength or inability to complete a single chair stand, a gait 
speed <0.8m/s, and an ALM < 5.67 kg/m2 or ALM/BMI <0.512.  Women were then 
classified as having low muscular strength, low lean mass, or low physical functioning 
(gait speed), or all three aspects.  
 Determining Arthritis Presence: Arthritis was based on self-report noted in 
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participants’ phone screening interviews and medical history questionnaires 
administered during pre-screening sessions.  The phone screening interview 
specifically asked about osteoarthritis/degenerative arthritis and the disease duration 
and severity.  The medical history questionnaire used a “yes/no” question to identify if 
the participant had arthritis as well as a separate "yes/no" question for gout.  Neither 
questionnaire asked about which joints were affected or for specifications on other 
types of arthritis (e.g. rheumatoid arthritis, fibromyalgia).  However, some participants 
chose to report what joints were affected by arthritis on the phone screening interview 
despite not being asked.  Participants were categorized as having non-specific arthritis 
if they reported arthritis (any kind affecting any joint(s)) and were also categorized 
into a subset for hand arthritis. 
 Grip Strength: Hand grip strength is used to identify muscular strength [34] 
and is a good predictor of frailty and disability with increasing age [13,17].  Grip 
strength is also a key factor in the current working definitions for sarcopenia [6,9].  
Grip strength was assessed using a hand grip dynamometer (Jamar Hydraulic 
Dynamometer, J.A. Preston, Corp., Jackson, MS) and was performed on both hands 
for two trials each with the highest score out of all four total trials being recorded in 
kilograms.  Participants were seated with the elbow flexed at 90 degrees.  The hand 
grip dynamometer was adjusted for each participant by ensuring all four fingers have 
the second knuckle placed flat on the handle.  Grip strength was measured during pre-
screening sessions and at the baseline assessment.   
 Single Chair Stands: Muscular strength was also assessed using a single chair 
stand during the pre-screening sessions.  Failure to rise from a chair unassisted is used 
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in the IWG working definition as criteria for identifying weakness [7].  The IWG 
recognizes that chair stands are considered an activity of daily living and require 
adequate muscular strength to complete this task [7,35]. 
 Gait Speed: The assessment of physical functioning is crucial as it 
characterizes an individual’s functional status and can determine mortality risk [36].  A 
four meter gait speed assessment was done twice with participants walking at a normal 
pace and the best score was used in determining sarcopenia status.  
 Body Composition: Body composition was assessed using an InBody 570 
SMF-BIA (Biospace Co, Ltd, Korea) device during the pre-screening visit as well as 
during baseline testing according to the manufacturer’s instructions.  The SMF-BIA is 
an accepted valid device used to estimate lean mass and is safe to use in older 
populations [37].  Measurements were taken at the right and left arms, the right and 
left legs, as well as for the trunk using 8 electrodes specifically placed and 6 different 
frequencies (1 kHz, 5 kHz, 50 kHz, 250 kHz, 500 kHz, 1000 kHz) which gave a total 
of 30 impedance measurements for each participant.  The SMF-BIA uses electrical 
conductivity to estimate lean mass after traveling through various tissues and 
differentiates between the tissues depending on their water content.  Lean mass 
contains higher amounts of water when compared to adipose tissue and therefore is a 
better conductor.  To standardize the assessment, all participants were asked to be 
hydrated and fasted for at least four hours. 
 Anthropometrics: Participants had their height, weight, and waist and hip 
circumferences measured twice.  Participants wore surgical scrubs for the waist and 
hip circumference measurements and a standard tape measure with a tensometer 
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(Gulick Tape Measure, Japan) was used to measure both the waist and hip.  The 
average of the two scores was used to calculate each participant’s BMI and waist-to-
hip ratio.  
 Strength Measures:  A chest press machine (Cybex International, Inc., 
Medway, MA) was used to assess upper body strength of each participant through 
methods previously published [38].  From a seated position, participants had their 
head, shoulders, and back against a seat back and held onto handles positioned at chest 
height.  Participants then extended their elbows fully and then returned to the starting 
position.  After a standard warm up, participants completed 3-5 sets of one repetition 
with gradually increasing weight and a three minute rest period between sets until their 
one repetition maximum (1RM) for chest press (CP1RM) was determined.  A 1RM for 
lower body muscular strength for each participant was determined using seated leg 
press machine (Cybex International, Inc., Medway, MA) using methods previously 
published [39].  Participants were seated and then extended their knees from the 
starting position (~90 degrees) by pushing against a platform with their feet until their 
knees were close to full extension but not locked.  After a standard warm up, 
participants completed 3-5 sets of one repetition with gradually increasing weight and 
a three minute rest period between sets until their 1RM for leg press (LP1RM) was 
determined.  
Other Measures 
 
 Physical Activity: The Yale Physical Activity Survey (YPAS) questionnaire 
was administered to evaluate participants’ physical activity levels and has been shown 
to be a valid assessment for determining physical activity levels among older adults.  
This questionnaire was used for describing participants’ baseline physical activity 
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levels [40].  
 Dietary Intake: The Dietary Screening Tool (DST) was administered to 
participants at baseline testing to assess their dietary patterns at to determine their 
level of nutritional risk [41].  There are three levels of nutritional risk that are used to 
identify if older adults are at risk including: at risk (<60), at possible risk (60-75), and 
not at risk (>75) [42].  This questionnaire was used to describe the baseline 
characteristics for the participants who partook in baseline testing for the randomized 
controlled trial.  
 Arthritis Medications and Analgesics: Arthritis and painkiller medication was 
based on self-report noted in each participant’s phone screening interviews and 
medical history questionnaires administered during pre-screening sessions.  Table 2 
depicts the number of participants who used each.  
Statistical Analysis 
 Estimated sample size for this study was determined based on anticipated 
between-group changes in lean mass rather than change in sarcopenia status by 
arthritis status.  This analysis is considered a pilot study to determine the potential for 
periodized resistance training to impact sarcopenia status and therefore could be 
underpowered. 
 The demographic and clinical characteristics for participants are expressed as 
mean ± standard deviation and frequencies.  A Shapiro-Wilk test was completed to 
ensure the data for the primary and secondary outcome variables were normally 
distributed.  Participants were grouped by non-specific arthritis status as well as well 
as a subset of that for hand arthritis status.  Independent samples t-tests were used to 
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compare those with and without non-specific arthritis to each other as well as those 
with and without hand arthritis to each other.  A Fisher’s exact test was used to assess 
hand arthritis status and its relationship to sarcopenia status, as well as non-specific 
arthritis status to sarcopenia status for the women who partook in screening 
measurements for the study (n=61).  To test the secondary hypothesis, a Pearson 
correlation was used to assess the relationship between grip strength, and upper and 
lower body muscular strength in those with hand arthritis, as well as those with non-
specific arthritis from participants who partook in the baseline assessments (n=25).  
Potential outliers were identified using a box-and-whisker plot and Tukey’s method.  
An alpha of p≤0.05 was used for all statistical analyses and all analyses were 
performed using both SPSS software (IBM SPSS, Version 22, Armonk, NY, 2013) 
and SAS software (SAS Institute, Cary, North Carolina).
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RESULTS AND DISCUSSION 
Results 
 Figure 1 depicts the flow of subject recruitment.  The analytical sample 
included 61 women (mean age=71.89±4.60 years) who were screened for participation 
in the randomized controlled trial.  There were 35 women who had non-specific 
arthritis and 26 women without arthritis.  Twelve of the 61 participants had hand 
arthritis, a subset of the non-specific arthritis, while 49 did not have hand arthritis.  
 Also, there were 25 women (mean age=72.23±4.63 years) selected from the 61 
women who completed all baseline measurements.  Of the 25 women, 15 women had 
non-specific arthritis and 10 did not have any arthritis.  In addition, there were 10 
women who had hand arthritis while there were 15 women who did not have hand 
arthritis. 
 In Tables 3 and 4, each group’s demographic characteristics, anthropometric 
measurements, performance based measures, and physical activity levels are 
presented.  For both the 61 women screened for the randomized controlled trial, and 
the 25 who partook in baseline measurements for the randomized controlled trial, they 
were divided into groups including those with non-specific arthritis and a subgroup for 
those with hand arthritis.  There were no significant differences in characteristics 
between those with non-specific arthritis to those without non-specific arthritis or 
those with hand arthritis and those without hand arthritis.  
 Mean grip strength for those with non-specific arthritis for participants who 
partook in screening assessments for the randomized controlled trial was 16.61±4.06 
kg (n=35), while those without arthritis had a mean grip strength of 18.88±5.29 kg 
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(n=26; p=0.063).   Mean grip strength was 17.58±4.72 kg overall and was 16.00±3.72 
kg for those with hand arthritis (n=12) and 17.97±4.89 kg (n=49; p=0.198) for those 
without hand arthritis for participants who partook in screening assessments for the 
randomized controlled trial. 
.  When comparing hand arthritis to sarcopenia status via grip strength and 
ability to perform a single chair stand, the Fisher’s exact test highlighted in Table 5, 
indicates that non-specific arthritis was not significantly related with sarcopenia status 
for participants who partook in the screening measurements for the randomized 
controlled trial (p=0.36).  In addition, in Table 6, the Fisher’s exact test indicates that 
hand arthritis was not significantly related with sarcopenia status (p=0.44) as well. 
Participants were considered to have grip dependent inclusion if their grip strength 
score was <20kg or if they cannot complete a single chair stand.  Non grip dependent 
inclusion described participants who had a grip strength score of >20kg or ALM/m2 
<5.67 or ALM/BMI <0.512 or gait speed <0.8m/s or met no sarcopenia criteria.                                                                                                                                             
 A Pearson’s correlation coefficient assessed the strength of the relationship 
between grip strength, CP1RM, and LP1RM for those with non-specific arthritis to 
those without arthritis for the participants who completed baseline measurements for 
the randomized controlled trial.  There were no significant relationships between grip 
strength and CP1RM (r=-0.183, p=0.515), grip strength and LP1RM (r=-0.330, 
p=0.230), and CP1RM and LP1RM (r=0.389, p=0.152).  However, if one outlier were 
removed whose grip strength score was >2.7 SD according to the box and whisker plot 
and Tukey method [43], grip strength and CP1RM, grip strength and LP1RM, and 
CP1RM and LP1RM still had no significant relationship (r=-0.226, p=0.438; r=-0.118, 
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p=0.688; r=0.389, p=0.152 respectively).  While for those with hand arthritis, there 
was also no relationship between grip strength and CP1RM (r=-0.212, p=0.556), grip 
strength and LP1RM (r=-0.521, p=0.122), and CP1RM and LP1RM (r=0.129, 
p=0.723).  Also, when removing the same outlier from those with non-specific 
arthritis, the results were not significantly altered as well (grip strength and CP1RM: 
r=-0.471, p=0.200, grip strength and LP1RM: r=-0.399, p=0.288, CP1RM and 
LP1RM: r = 0.129, p=0.723).  
Discussion 
 The major finding of this study was that hand arthritis was not related to 
sarcopenia status in this population of older women.  Grip strength was not 
significantly different between groups for those with non-specific arthritis compared 
to those without and it was also not significantly different between those with hand 
arthritis and those without arthritis.  To our knowledge, this present study is the first to 
address hand arthritis to sarcopenia status in older women with or without symptoms 
of sarcopenia.  
 Although this study found no relationship between hand arthritis and 
sarcopenia status via grip strength or failure to perform a single chair stand, it was 
hypothesized that there may be a relationship based on findings in recent literature.  
Muscular strength is a component of the working definitions for sarcopenia and is 
often assessed using a grip strength test.  Many studies have reported that grip strength 
is negatively affected by various forms of arthritis [28-32].  A study by Bagis et al. 
(2003) compared the relationship between osteoarthritis and grip strength scores in 
postmenopausal women.  In that study, those with osteoarthritis had significantly 
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decreased grip strength scores for both hands when compared to those without 
osteoarthritis (19.57±6.16 kg versus 21.88±5.51 kg, 19.16±6.16 kg versus 22.11±5.67 
kg, right and left hand respectively, p<0.05).  Also, with increasing severity of 
osteoarthritis (based on the grade of osteoarthritis 0-4), the highest grade osteoarthritis 
was significantly associated with lower grip strength scores than healthy individuals 
and those with other grades of osteoarthritis (p<0.001).  The average grip strength 
scores of those with osteoarthritis on both hands were significantly lower than those 
without osteoarthritis and would meet the sarcopenia criteria used by the EWGSOP 
for muscular strength (grip strength <20kg) [6].  Therefore, since a cut-point of <20kg 
was used to classify participants used in our study, it was hypothesized that arthritis 
may be related to sarcopenia status.   
 Also, the IWG sarcopenia working definition utilizes an alternative measure 
for quantifying muscular strength.  Instead of grip strength, the IWG uses the ability to 
perform a single chair stand as their measure since the ability to rise from a chair is an 
important activity of daily living and requires adequate muscular strength [35].  
However, osteoarthritis in the knee and hip are related to lower, lower extremity 
muscular strength and could make it more difficult to perform lower body assessments 
[44]. 
 This study also suggests that grip strength and upper and lower body muscular 
strength for those with non-specific arthritis as well as hand arthritis were not related 
to each other.  However, other studies have reported that grip strength and lower body 
muscular strength are related, and that using grip strength as a measure for overall 
muscular strength is an adequate alternative for older individuals [11,46].  Grip 
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strength is also known to be a good indicator of upper body strength as well [11,47]. 
However, given the results of this study, grip strength may not be a valid tool for 
overall muscular strength for those with arthritis since there was no relationship 
between grip strength and other measures of upper and lower body strength.  
Additionally, arthritis is known to cause pain and pain attenuates muscular strength 
ability [44].  It is unknown to what extent our population of women were experiencing 
arthritis related pain and if analgesics and arthritis medication helped relieve any 
symptoms.  Therefore it makes it difficult to conclude the reason for a lack of 
relationship between grip strength, CP1RM, and LP1RM, in this population of older 
women.  
 Also, other studies have demonstrated that various forms of arthritis are related 
to other sarcopenia criteria [31,33,44,45].  In a study conducted by Kemmler et al. 
(2016), they found that participants with osteoarthritis at the hip and lower limbs were 
more likely to be classified as sarcopenic according to the EWGSOP working 
definition.  Those with osteoarthritis performed more poorly when assessed for gait 
speed and grip strength (p<0.001).  However, lean mass in those with osteoarthritis 
was higher than those without osteoarthritis [31].  This is different than findings from 
two studies that looked at body composition in those with rheumatoid arthritis [33,45].  
The study by Dogan et al. (2015), assessed sarcopenia in women with rheumatoid 
arthritis and found that those with rheumatoid arthritis had lower ALM than their 
normal counterparts [33].  Similarly, in a study by Giles et al. (2008), men and women 
with rheumatoid arthritis had lower ALM compared to those without rheumatoid 
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arthritis as well [45].  Various forms of arthritis should be addressed to all components 
of sarcopenia criteria to see if there is a relationship.  
 This study has a few strengths worth noting.  First, this study included a 
homogenous sample cohort of community-dwelling older women.  Second, to our 
knowledge this is the first study to assess hand arthritis and its relationship to 
sarcopenia status in older women with or without symptoms of sarcopenia based on 
newly established sarcopenia guidelines.  Finally, this study used measures of 
muscular strength that have been standardized and validated for older populations 
[38,39]. 
 Despite these study strengths, there were some limitations.  First, the sample 
size of our study was small and was not designed to specifically examine the 
relationship between hand arthritis to sarcopenia status.  Therefore, the results may not 
adequately reflect this relationship.  In addition, we did not ask participants to specify 
on the type of arthritis that they had except for osteoarthritis/degenerative arthritis or 
what areas of the body were affected but some chose to report it.  Therefore, these data 
on hand arthritis and association with physical functioning should be approached 
degree of a caution.   
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CONCLUSION 
 This is the first study to evaluate hand arthritis to sarcopenia status via grip 
strength or failure to complete a single chair stand in a population of older women 
with or without symptoms of sarcopenia.  Although the present study found that non-
specific arthritis and the subset, hand arthritis, were not significantly related to 
sarcopenia status, additional studies with a larger sample size and clearly defined 
arthritis status are needed to determine if these variables are linked.  Osteoarthritis and 
rheumatoid arthritis are two common forms of arthritis known to affect the joints of 
the hand and are reported to affect grip strength scores [24,26,30,31].  Other common 
forms of arthritis including gout [51], which primarily affects the metatarsophalangeal 
joint, and fibromyalgia [52-54], which is characterized by widespread pain, do not 
commonly affect the hand joints.  Therefore, those two forms of arthritis should be 
evaluated for their relationship to sarcopenia status as well as if disease severity and 
duration affect sarcopenia classification.  
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TABLES  
Table 1.  Inclusion and exclusion criteria used for study recruitment 
Inclusion Criteria 
 Women, ages 65-84 years 
 Low physical functioning, and/or low lean muscle mass based on current sarcopenia 
guidelines 
 Currently (≥6 months) not engaged in regular exercise programs 
 Post-menopausal by self-report 
 BMI 18.5-45.0 kg/m2 
Exclusion Criteria 
 Failure to provide informed consent 
 Significant or suspected cognitive impairment 
 Severe hearing loss, speech disorder, language barrier, or visual impairment 
 Progressive or degenerative neurological disease 
 Severe pulmonary disease, uncontrolled diabetes, blood pressure, or anemia 
 Any medication changes within the past 3 weeks, or lipid lowering medication changes 
within the past 6 months 
 Major joint, vascular, abdominal, or thoracic surgery within the past 6 months 
 Significant cardiovascular disease or implanted pacemaker or defibrillator 
 Inability to safely engage in mild to moderate exercise with muscular exertion 
 Inability to speak and read in English 
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Table 2. Arthritis and analgesic medication use for women screened for the 
randomized controlled trial and the women who partook in baseline testing for the 
randomized controlled trial. 
Type of Medication Over the Counter 
(OTC)/ 
Supplements 
Prescribed (oral 
and topical) 
Not specified- 
OTC/Supplements 
Arthritis 
Medication 
2 4 1 
Painkiller 
Medication - 
NSAID 
6 1 0 
Abbreviation: NSAID, nonsteroidal anti-inflammatory drug 
  
  
2
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Table 3. Characteristics of those without non-specific or hand arthritis, non-specific arthritis, and hand arthritis in participants who 
completed the screening measurements for the randomized controlled trial (n=61). 
 Mean ± (SD) Non-specific 
Arthritis         
(n=35, 57.4%) 
Non-Arthritis 
(n=26, 42.6%) 
P- value Hand Arthritis 
(n=12, 19.7%) 
Non Hand 
Arthritis          
(n=49, 80.3%) 
P-value 
Age (yrs) 71.89± 4.60 72.03± 4.68 71.69± 4.58 0.780 71.50± 4.21 71.98± 4.73 0.749 
Weight (kg) 70.88± 15.19 70.87± 15.06 70.87± 15.64 0.999 75.60± 18.82 69.71± 14.15 0.232 
Height (cm) 160.84± 5.64 160.11± 5.29 161.81± 6.04 0.247 160.48± 4.10 160.92± 5.99 0.810 
BMI (kg/m2) 27.31± 5.96 27.65± 5.83 27.09± 6.02 0.717 29.40± 7.64 26.93± 5.34 0.194 
 % Body Fat 40.05± 7.60 40.62± 7.95 39.29± 7.19 0.505 41.56± 8.24 39.69± 7.48 0.449 
Grip Strength (kg) 17.58± 4.72 16.61± 4.06 18.88± 5.29 0.063 16.00± 3.72 17.97± 4.89 0.198 
Gait Speed (meters/ 
second) 
1.02± 0.17 0.99± 0.17 1.06± 0.17 0.131 1.04± 0.18 1.02± 0.17 0.685 
Abbreviation: BMI, Body Mass Index                                                                                                                                                                                                                                            
% Body Fat measured using InBody 570 SMF-BIA, Biospace Co, Ltd, Korea                                                                                                                                                                               
P-values were obtained using independent samples t-tests                                                                                                       
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Table 4.  Characteristics of those without non-specific or hand arthritis, non-specific arthritis, and hand arthritis for participants who 
completed baseline measurements for the randomized controlled trial (n=25). 
 Mean ± (SD) Non-specific 
Arthritis (n=15, 
60.0%) 
Non-Arthritis 
(n=10, 40.0%) 
P-value Hand Arthritis 
(n=10, 40.0%) 
Non Hand 
Arthritis (n=15, 
60.0%) 
P-value 
Age (yrs) 72.23± 4.63 71.93± 4.57 72.90± 4.89 0.619 73.10± 4.12 71.80± 5.00 0.503 
Weight (kg) 65.36± 13.47 62.89± 10.87 69.06± 16.57 0.271 61.25± 9.66 68.10± 15.20 0.220 
Height (cm) 159.78± 5.15 159.87± 4.81 159.64± 5.90 0.915 159.54± 4.97 159.94± 5.44 0.855 
BMI (kg/m2) 25.70± 5.86 24.63± 4.31 27.30± 7.61 0.274 24.06± 3.67 26.79± 6.86 0.263 
Waist to Hip Ratio 0.87± 0.10  0.88± 0.11 0.86± 0.09 0.745 0.84± 0.09 0.89± 0.10 0.150 
% Body Fat 37.14± 7.66 36.03± 7.74 38.82± 7.62 0.383 34.76± 6.98 38.73± 7.91 0.211 
Grip Strength (kg) 16.64± 3.74 16.60± 4.01 16.70± 3.51 0.949 16.30± 4.81 16.87± 3.00 0.719 
Gait Speed (meters/ 
second) 
1.05± 0.14 1.07± 0.15 1.02± 0.13 0.359 1.04± 0.12 1.05± 0.16 0.813 
Chest Press 1 RM 
(kg) 
17.01± 6.64 15.38± 3.93 19.46± 9.09 0.136 14.21± 3.73 18.89± 7.57 0.084 
Leg Press 1 RM (kg) 46.34± 16.13 41.91± 7.51 52.98± 22.91 0.093 40.01± 6.46 50.56± 19.28 0.111 
Physical Activity 
(kcals/ week) 
7302± 3030 7107± 2663 7574± 3615 0.719 7162± 2753 7386± 3275 0.866 
Physical Activity 
Index 
49.46±   21.89 50.79± 20.06 47.60± 25.22 0.734 47.70± 20.19 50.71± 23.69 0.747 
DST 69.2±7.8 70.85± 8.99 67.10± 5.61 0.262 69.56± 9.75 69.00± 6.62 0.872 
Abbreviation: BMI, Body Mass Index, DST, Dietary Screening Tool                                                                                                                                                                                                     
% Body Fat measured using InBody 570 SMF-BIA , Biospace Co, Ltd, Korea                                                                                                                                                                              
Physical Activity (PA) from the Yale Physical Activity Survey (YPAS)                                                                                                                                                                                           
YPAS and PA Index mean±SD reflect n=24 due to incomplete/missing surveys                                                                                                                                                                            
Dietary Screening Tool: At Risk (<60), Possible risk (60-75), Not at risk (>75), mean±SD reflect n=23 due to incomplete/missing surveys                                                                                                                                       
P-values were obtained using independent samples t-tests                                                                                                       
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Table 5. Fisher’s exact test for non-specific arthritis and its relationship to sarcopenia 
status in older women with or without symptoms of sarcopenia 
 Arthritis – Yes Arthritis – No Total 
Grip Dependent 
Inclusion 
18 10 28 
Non Grip Dependent 
Inclusion 
17 16 33 
Total 35 26 61 
Grip Dependent Inclusion, Grip Strength <20kg or failed to complete a single chair stand                             
Non Grip Dependent Inclusion, Grip Strength >20kg or ALM/m2 <5.67 or ALM/BMI <0.512 or gait speed 
<0.8m/s or no criteria met                                                                                                                                
NOTE: No differences between groups (p=0.36) 
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Table 6.  Fisher’s exact test for hand arthritis and its relationship to sarcopenia status 
in older women with or without symptoms of sarcopenia. 
 Hand Arthritis – Yes Hand Arthritis – No Total 
Grip Dependent 
Inclusion 
7 21 28 
Non Grip Dependent 
Inclusion 
5 28 33 
Total 12 49 61 
Grip Dependent Inclusion, Grip Strength <20kg or failed to complete a single chair stand                             
Non Grip Dependent Inclusion, Grip Strength >20kg or ALM/m2 <5.67 or ALM/BMI <0.512 or gait speed 
<0.8m/s or no criteria met                                                                                                                                                  
NOTE: No differences between groups (p=0.44) 
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FIGURES 
Figure 1. Study Flow Chart 
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APPENDICES 
APPENDIX A: Review of the Literature 
 
Abstract 
The loss of muscular strength, physical functioning, and lean mass with age that 
contributes to disability and frailty is designated as sarcopenia.  Older women are at an 
increased risk for developing sarcopenia compared to men due to faster declines in 
muscular strength and lean mass that assist in developing physical disabilities. There is 
no universally accepted working definition for sarcopenia but many organizations 
have established their own working definitions based on low lean mass, slowness, and 
weakness to deem individuals as sarcopenic.  Muscular strength is a key component of 
sarcopenia and is measured via grip strength.  While using grip strength to assess 
overall muscular strength is a common practice, potential challenges may arise when 
conditions that limit hand functionality, such as arthritis, are present.  Arthritis is 
characterized by inflammation and joints stiffness, which can cause deformities to 
develop as well as decrease overall hand functionality.  Therefore the limited hand 
functionality due to arthritis may impair grip strength scores and affect sarcopenia 
classification despite adequate muscular strength and physical functioning in other 
areas of the body.  No study to date has assessed if hand arthritis is related to 
sarcopenia classification in older women with symptoms of sarcopenia.  
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Introduction 
 
 Sarcopenia is characterized by a loss of muscular strength, functionality, and 
lean mass with increasing age (Manini & Clark, 2012; Rosenberg, 1989)  that is 
related to the development of functional limitations  (Beaudart, Rizzoli, Bruyère, 
Reginster, & Biver, 2014).  This geriatric disease is multifactorial and develops from 
muscle disuse, nutritional deficiencies, dysfunction of the endocrine system, and 
chronic diseases identified with muscle loss (Fielding et al., 2011).  This promotes 
muscular atrophy and a reduction in type II muscle fibers (Alchin, 2014; Delmonico & 
Beck, 2015; Maltais, Desroches, & Dionne, 2009).  After the age of 50, lean mass is 
lost at approximately a rate of 1-2% per year (Marcell, 2003).  This decline in lean 
mass is associated with many adverse health outcomes including an increased risk for 
fractures and falls, a decrease in physical functionality, decreased independence, and 
declines in muscular strength (Melton et al., 2000; Scott et al., 2014; Zeng et al., 
2016).  In addition, in 2000, the estimated health care costs of sarcopenia for women 
alone were $29.5 billion and were $12.6 billion for older men (Janssen, Shepard, 
Katzmarzyk, & Roubenoff, 2004).  Sarcopenia is a public health problem that will 
continue to be an economic burden as the older population continues to increase.  
Women make up the majority of the elderly population worldwide due to their greater 
life expectancy and they have an increased risk for functional disability due to quicker 
declines in muscular mass and strength (Borst, 2004; Centers for Disease Control and 
Prevention (CDC), 2016c; Idland, Pettersen, Avlund, & Bergland, 2013).  
 Currently, there is no universal working definition for sarcopenia but national 
and international organizations have established their own criteria used for sarcopenia 
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and vary depending on the organization (Cruz-Jentoft et al., 2010).  Among these 
several organizations that have established their own working definitions, there are 
The European Working Group on Sarcopenia in Older People (EWGSOP), the 
International Working Group (IWG), and The Foundation for the National Institutes of 
Health Sarcopenia Project (FNIHSP).  These three groups all use similar criteria in 
their working definitions, including measures of muscular strength, gait speed, and a 
measure of lean mass to confirm sarcopenia status (Cruz-Jentoft et al., 2010; Fielding 
et al., 2011; McLean et al., 2014).   
 While there are various techniques to assess muscular strength and there exist 
variations with how it is assessed in the working definitions, grip strength is a 
commonly used test for muscular strength.  It is considered a valid measure of overall 
muscular strength and is predictive of health outcomes including frailty, disability, and 
mortality  (Bohannon, 2008; C. Cooper et al., 2013; Rantanen et al., 1999a; Syddall, 
Cooper, Martin, Briggs, & Aihie Sayer, 2003; Visser, Deeg, Lips, Harris, & Bouter, 
2000).  However, functional limitations from diseases in the hand such as arthritis are 
known to be associated with decreased grip strength scores (Bagis, Sahin, Yapici, 
Cimen, & Erdogan, 2003; Cardoso Fde, Curtolo, Natour, & Lombardi Junior, 2011; 
Dedeoğlu, Gafuroğlu, Yilmaz, & Bodur, 2013; Huang et al., 2013; Kemmler et al., 
2015; Koca et al., 2016).  The limited hand functionality due to arthritis may therefore 
influence sarcopenia classification via grip strength measures despite adequate 
muscular strength in other major muscle groups and physical functioning.  While some 
studies have shown that hand arthritis does influence grip strength, it has not been 
addressed how hand arthritis may influence sarcopenia classification. 
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. Sarcopenia in Older Women   
 Older adults are at a higher risk for sarcopenia, especially women because they 
make up the majority of the elderly population due to their longer life expectancy of 
approximately 4.8 years (Centers for Disease Control and Prevention (CDC), 2016c).   
Women have higher prevalence for declines in muscular strength, functional 
impairments, and declines in lean mass when compared to men and often occur earlier 
in life due to menopause.  Menopause leads to various changes in hormonal 
concentrations and causes estrogen levels to decline (Batsis, Mackenzie, Barre, Lopez-
Jimenez, & Bartels, 2014; Carriere et al., 2005; Maltais et al., 2009).  
Declines in estrogen are accompanied by declines in IGF-1, a protein involved 
in muscle protein synthesis, which in turn cause pro-inflammatory cytokines levels to 
increase. Pro-inflammatory cytokines are known to contribute to muscle breakdown 
and sarcopenia (Ferrucci et al., 2002; Maltais et al., 2009; Visser et al., 2002).  
Additionally, there is an increase in visceral fat mass and decreases in bone mineral 
density, as well as atrophy of type II muscle fibers which causes a diminished power 
output with increasing age among older women (Maltais et al., 2009).   
  Muscular strength plays a key role in physical functioning as well as overall 
quality of life (Maltais et al., 2009).  Therefore, it is important that early identification 
of decreased physical function is recognized so proper intervention can be implicated 
to prevent the development of further functional disability.  For example, a nine year 
prospective cohort study in Norway assessed modifiable risk factors for activities of 
daily living (ADL) disability in 113, non-disabled community-dwelling older women 
(mean age=79.5 years) from a census file of women who had randomly been selected 
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for a separate study on falls.  At baseline, the participants completed a comfortable 
walking speed test, a step climbing test, and a functional reach test to assess physical 
performance. To assess ADL disability, a modified Avlund PADL-H scale was used 
with questions pertained to needing assistance in five basic ADL categories at baseline 
and follow-up (9.3 years).  After adjusting for all three measures in the same model, 
comfortable walking speed was significantly associated with the onset of ADL 
disability (OR=0.4, 95% CI:0.02-0.69).  However, both the step climbing and 
functional reach tests were not significantly associated with the onset of ADL 
disability after adjusting for all three performance measures in the same model 
(OR=0.97, 95% CI:0.93-1.02, OR=0.94, 95% CI:0.89-1.02 respectively).  In addition, 
for every 0.1 m/s slower walking speed, the risk for ADL disability increased by 60% 
(Idland et al., 2013).  Other measurements to predict disability onset from should be 
employed as well (Rantanen et al., 1999a; Rantanen et al., 1999b).  
Working Definitions for Sarcopenia 
 
Sarcopenia is complicated as it is a multifactorial disease with no established 
universal definition.  Currently, there are only working definitions for sarcopenia due 
to the lack of a widely accepted clinical definition (Cruz-Jentoft et al., 2010).  Several 
organizations have established their own working definitions for sarcopenia but vary 
slightly in their criteria which presents a challenge when determining which 
individuals are at risk.  Additionally, sarcopenia is sometimes classified based on its 
severity in various definitions due to its prolonged development over extended periods 
of time  (Cruz-Jentoft et al., 2010; McLean et al., 2014).  Previously, the criteria for 
sarcopenia were based on muscular mass alone compared to a reference population.   
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However, now the sarcopenia working definitions include performance criteria as well 
(Correa-de-Araujo & Hadley, 2014).  In clinical practice, muscular mass can be 
assessed using various techniques including dual energy x-ray absorptiometry (DXA), 
segmental multi-frequency bioelectrical impedance analysis (SMF-BIA), as well as 
anthropometry measurements.  Hand grip strength is assessed via a handheld 
dynamometer and is used to assess overall muscular strength.  It is a good measure of 
strength and correlates well other parts of the body (Cruz-Jentoft et al., 2010; 
Lauretani et al., 2003; Visser et al., 2000).  In addition, physical functioning is 
assessed using gait speed, the short physical performance battery (SPPB) test, as well 
as the get up and go test (Working Group on Functional Outcome Measures for 
Clinical Trials, 2008).  National and international organizations that define sarcopenia 
based on muscular mass and performance criteria include the EWGSOP, the IWG, and 
the FNIHSP.  While previous working definitions only used measurements of 
muscular mass, current working definitions, including the EWGSOP, IWG, and 
FNIHSP, use measurements of muscular mass as well as performance criteria to 
determine sarcopenia status (Cruz-Jentoft et al., 2010; Fielding et al., 2011; McLean et 
al., 2014; Studenski et al., 2014).  
The EWGSOP working definition states that to be sarcopenic, low lean mass 
as well as slowness or weakness must be present (Correa-de-Araujo & Hadley, 2014; 
Cruz-Jentoft et al., 2010).  The EWGSOP quantifies low lean mass using appendicular 
lean mass (ALM) divided by height squared (ALM/ht2) and uses the criteria of 
<5.67kg/m2 for women.  In regards to muscular strength, the EWGSOP uses a grip 
strength test and has a cutpoint of <20 kg for women.  To be considered slow, the 
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EWGSOP uses a gait speed of <0.8 meters per second (m/s) as the criteria for women.  
Also, the EWGSOP characterizes the severity of sarcopenia and classifies individuals 
as having presarcopenia, sarcopenia, or severe sarcopenia.  Presarcopenia requires 
individuals to have just low lean mass, while sarcopenia again, requires individuals to 
have low lean mass and either be slow or weak.  To be classified as severely 
sarcopenic, individuals must present with all three criteria: low lean mass, slowness, 
and weakness (Correa-de-Araujo & Hadley, 2014; Cruz-Jentoft et al., 2010)  
The IWG working definition describes sarcopenia as complex disease that 
encompasses a decline in physical functioning as well as a decline in muscular mass  
(Fielding et al., 2011).   The IWG therefore states that older individuals who are weak, 
have low physical functioning or poor health should be evaluated (Fielding et al., 
2011).   In addition, the IWG suggests evaluating older individuals who have difficulty 
performing activities of daily living such as rising from a chair or walking for 
sarcopenia  (Fielding et al., 2011).  Performing such activities of daily living require 
adequate muscular strength (Rolland et al., 2008) and is reflected in their measures of 
muscular strength and physical functioning (Fielding et al., 2011).   To assess 
muscular strength, the IWG uses a failure to complete an unassisted single chair stand 
as its criteria  (Fielding et al., 2011).   If an individual can complete a chair stand 
unassisted, then the IWG states they should complete a gait speed test (Fielding et al., 
2011).   The criteria for gait speed is <1.0 m/s for women which is slightly slower than 
what the EWGSOP uses (<0.8 m/s) (Cruz-Jentoft et al., 2010; Fielding et al., 2011).  
In addition, if an individual’s gait speed is <1.0m/s, their lean mass should be assessed 
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and is considered low lean mass for women if their ALM/ht2 is <5.67 kg/m2 (Fielding 
et al., 2011).  
 Unlike the EWGSOP, the FNIHSP does not characterize individuals as 
sarcopenic or severely sarcopenic, but either as those with “weakness with low lean 
mass,” or “weakness and slowness with low lean mass” (McLean et al., 2014).  The 
FNIHSP suggests based on their clinical model that individuals be screened for 
physical functioning limitations followed by weakness and low lean mass (Studenski 
et al., 2014).   To assess physical functioning, the FNIHSP uses a gait speed cut off of 
<0.8 m/s for women, which is similar to what the EWGSOP uses.  The FNIHSP also 
uses grip strength like the EWGSOP to assess muscular strength, but has a more 
conservative cut point of <16 kg for women compared to <20 kg (Alley et al., 2014; 
Cruz-Jentoft et al., 2010).  Also, unlike both the EWGSOP and IWG, the FNIHSP 
characterizes low lean mass by the ratio of ALM to BMI instead of height squared and 
uses an established cut point for <0.512 for women (McLean et al., 2014).  
The inability to agree on a universal working definition has made determining 
sarcopenia status and incidence and prevalence rates difficult to compare across 
groups.  Depending on the working definitions used, prevalence numbers vary.  In a 
review conducted by Dam, et al. (2014), they compared prevalence in the EWGSOP, 
IWG, and FNIHSP working definitions.  When applying the EWGSOP definition, 
more women and men (13.3% and 5.3%) were considered sarcopenic when compared 
to the FNIHSP (2.3% and 1.3%) and IWG (11.8% and 5.1%) criteria. Additionally  
they found that the EWGSOP and FNIHSP criteria were more similar to each other 
due to their working definitions including measures in lean mass, muscular strength, 
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and/or physical functioning (Dam et al., 2014).  While the IWG includes measures of 
low lean mass in conjunction with declines in function.  Additionally, the IWG uses 
<1.0m/s instead of <0.8m/s, which is used by both the EWGSOP and FNIHSP, and 
assesses muscular strength differently than those two working groups (Dam et al., 
2014; Fielding et al., 2011).  However, when comparing the EWGSOP and IWG to the 
FNIHSP, the FNIHSP quantifies lean mass differently than the EWGSOP and IWG 
and uses ALM/BMI rather than ALM/ht2 (Dam et al., 2014).  The lack of a general 
consensus makes assessing those for sarcopenia difficult and establishing effective 
interventions challenging. 
Muscular strength is included in the EWGSOP, IWG, and FNIHSP sarcopenia 
working definitions.  Although it is thought that declines in muscular strength should 
be characterized separately (i.e. dynapenia from sarcopenia), dynapenia is similar to 
sarcopenia in that both are multifactorial conditions that are age related.  In addition, it 
is suggested that muscular strength is closely related to muscle mass and the working 
definitions for sarcopenia include measures of muscular strength and muscle mass 
(Clark & Manini, 2008).  
Grip Strength   
Hand grip strength is a common measure used in sarcopenia classification and 
has been associated with increased risks for frailty and mortality (Bohannon, 2008; 
Rantanen et al., 1999a; Rantanen et al., 1999b; Syddall et al., 2003).  To assess 
muscular strength, isokinetic dynamometry can be used or a hand-held dynamometer 
can be used (Stark, Walker, Phillips, Fejer, & Beck, 2011).  However, hand grip 
strength as a measure of muscular strength has been validated to the current gold 
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standard which is isokinetic dynamometry (C. Cooper et al., 2013; Stark et al., 2011).  
A review conducted by Stark, T., et al. (2011), found minor differences between hand-
held dynamometry and isokinetic dynamometry and concluded that a hand-held 
dynamometer is a reliable and valid instrument (Stark et al., 2011).  In addition, 
compared to isokinetic dynamometry, using a hand grip dynamometer is more cost 
effective and is easy to administer to large populations due to its compact size and 
portability allowing for clinical use (C. Cooper et al., 2013; Rantanen et al., 1999a; 
Stark et al., 2011).  Grip strength should be used frequently as it is highly predictive 
and is pertinent to specific populations such as middle-aged and older adults where the 
risk for developing functional issues and frailty are high (Bohannon, 2008; Syddall et 
al., 2003).   
Numerous studies have shown the ability of hand grip strength to predict 
adverse health outcomes including mortality and frailty.  In a longitudinal study that 
used 3,075 men (n=1124, mean age=73.7±2.9 years) and women (n=1168, mean 
age=73.4±2.8 years) from the from the Health, Aging and Body Composition (ABC) 
study and followed them for approximately 4.9±0.9 years.  At baseline, participants 
were assessed on hand grip strength and other measures.  That study found decreased 
grip strength was significantly related to increased mortality risk for men (HR=1.36, 
95% CI:1.13-1.64) and for women (HR=1.84, 95% CI:1.28-2.65) (Newman et al., 
2006).   
Similar results were seen in a meta-analysis conducted by Cooper, R. et al. 
(2010), that included 13 studies which used 44,636 participants, evaluated physical 
capabilities in relation to mortality in community-dwelling populations as well.  It was 
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found that with every increase in grip strength by 1 kg, there was a decrease in 
mortality risk and that the mortality summary hazard ratio (HR) was 1.67 (95% 
CI:1.45-1.93) when comparing the strongest and weakest quarter for grip strength (R. 
Cooper, Kuh, Hardy, Mortality Review Group, & FALCon and HALCyon Study 
Teams, 2010).  
Future disability can also be predicted via grip strength and numerous studies 
have evaluated this (Rantanen et al., 1999a; Rantanen et al., 1999b).   A 25 year 
prospective cohort study that looked at grip strength and disability was done by 
Rantanen, et al. (1999a), and evaluated healthy Japanese American men who resided 
in Oahu, Hawaii.  Their aim was to see if grip strength during mid-life could predict 
functional disability with increasing age in healthy men.  That study used 6,089 men 
(mean age=54.0±5.5 years) from both the Honolulu Heart Program and Honolulu-Asia 
Aging Study.  The participants completed a hand grip strength assessment at multiple 
time points as well as a gait speed assessment and an unassisted chair stand test.  To 
assess each participant’s disability status, questions on heavy household work, self-
care, and mobility were asked.  Only 3,218 participants completed follow up tests and 
the participants were divided into three groups (tertiles) based on their baseline hand 
grip strength scores.  That study found that lower baseline hand grip strength scores 
(lowest tertile) were associated with an increased risk for functional limitations and 
disability over the 25 year period.  The lowest tertile had an adjusted HR for a walking 
speed ≤ 0.4m/s of 2.77 (95% CI:1.70-4.54) and an adjusted HR of 2.73 (95% CI:1.19-
6.27) for unable to rise from a chair.  That study concluded that middle-aged men with 
higher grip strengths at baseline were at a decreased risk for disability and functional 
 43 
 
limitations into old age (Rantanen et al., 1999a).  While that study adequately showed 
that grip strength could predict disability and functional limitations, it only used older 
Japanese-American men. 
Another study that evaluated how grip strength predicts disability was a cross-
sectional analysis study that looked at 1,002 disabled women age 65 years and older 
(mean age=78.3±8.1 years) from The Women’s Health and Aging Study.  To assess 
muscular strength, hand grip and knee extension strength were assessed using hand-
held dynamometers.  Disability was assessed via self-reported challenges with specific 
activities such as walking across a small room, walking a quarter mile, as well as 
doing heavy housework.  In addition, participants were asked about their current 
physical activity levels via questionnaire and other chronic diseases they have.  That 
study found that with increased disability levels, grip strength and knee extension 
strength scores decreased (p<0.001).  In addition, age was negatively correlated with 
grip strength (r=-0.092, p=0.005) and knee extension strength (r=-0.082, p=0.0.14), 
but positively correlated with disability (r=0.075, p=0.019).  That study concluded that 
the findings suggested that increases in disability were likely related to muscular 
strength (grip strength and knee extension strength) decline (Rantanen et al., 1999b).  
Both of these studies reflect the ability of hand grip strength to predict future 
disability. 
 Additionally, there are also many types of hand grip dynamometers protocols 
that can be used to assess hand grip strength (Innes, 1999; Roberts et al., 2011).  
According to a review conducted by Roberts, et al. (2011), the Jamar hand grip 
dynamometer is the most widely used in the literature and concluded that it is likely 
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the gold standard  (Roberts et al., 2011).  Some protocols address hand size and hand 
dominance which influence the results and make comparing different hand 
dynamometers difficult  (Roberts et al., 2011).  In addition, there are hand grip 
dynamometers that can assess both static and dynamic muscular strength but static 
measurements are more commonly used  (Innes, 1999).  Hand grip dynamometers can 
be classified in four categories including hydraulic, pneumatic, mechanical, and strain 
instruments.  The Jamar hand grip dynamometer is an example of a hydraulic 
dynamometer and assess the amount of force applied (Innes, 1999).  Hand-held 
dynamometers are commonly used and a recommended tool to assess muscular 
strength but a lack of a standardized protocol makes comparing grip strength between 
studies difficult.  In addition, grip strength may not be the best measurement to use 
when functional limitations such as arthritis are present and alternative dynamometers 
more suitable should be used.  
Arthritis 
Arthritis is a chronic musculoskeletal disease that is characterized by joint 
stiffness and inflammation, which can often result in deformities of the joint from 
alterations of the joint structure (i.e. bone, ligaments, joint capsule). This also leads as 
decreased functionality of the affected joint (Cima, Barone, Porto, & de Abreu, 2013; 
Hootman, Helmick, & Brady, 2012; Johnsson & Eberhardt, 2009; Osteras et al., 
2014).  In 2003, arthritis cost the US $128 billion in direct and indirect costs (Centers 
for Disease Control and Prevention (CDC), 2013).  It is likely that those costs are 
higher as that with increasing age, arthritis prevalence gradually increases and will 
continue to be more abundant due to older adults living longer (Hootman et al., 2012).  
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On average in 2013-2015, approximately 54.4 million adults had arthritis and it was 
more prevalent in women than men (Barbour, Helmick, Boring, & Brady, 2017).  It is 
expected that by 2040, approximately 78.4 million U.S. adults will have doctor-
diagnosed arthritis (Hootman, Helmick, Barbour, Theis, & Boring, 2016).  
Arthritis is also the leading cause of disability in the U.S. and can decrease 
overall quality of life (Hootman et al., 2012; Song, Chang, & Dunlop, 2006).  In 
addition, there are over 100 types of arthritic diseases that affect the tendons, 
ligaments, muscles, and the joints, including osteoarthritis (OA), rheumatoid arthritis 
(RA), gout, and fibromyalgia (FM) (Hootman et al., 2012).  While the most common 
form of arthritis is osteoarthritis, rheumatoid arthritis, gout, and fibromyalgia are 
common as well (Centers for Disease Control and Prevention (CDC), 2017a; Hootman 
et al., 2012).  
Types of Arthritis: 
Osteoarthritis is a multifactorial disease that leads to pain, a decline in 
functionality, as well as deformity (Berenbaum, 2013; Centers for Disease Control and 
Prevention (CDC), 2017b; Loeser, Goldring, Scanzello, & Goldring, 2012).  Sex, 
previous injury to a joint, genetics, obesity, as well as other mechanical factors, and 
age, which is the strongest risk factor, all contribute to the development of OA 
(Centers for Disease Control and Prevention (CDC), 2017b; Loeser et al., 2012; Neogi 
& Zhang, 2013).  In addition, the development of OA stems from many pathological 
changes that occur in the joint cavity and include changes to the articular cartilage, 
changes to the subchondral bone, as well as inflammation to the synovial lining 
(Berenbaum, 2013; Loeser et al., 2012).  Changes in subchondral bone elements affect 
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the calcified cartilage, which lies between the subchondral bone and articular cartilage, 
and causes it to extend into the articular cartilage. This leads to thinning of the 
articular cartilage.  In addition, articular cartilage matrix proteins are degraded and can 
cause increased matrix degradation from a positive feedback loop that includes pieces 
of proteins that lead to inflammatory cytokine and chemokine production which 
contribute to synovitis (Loeser et al., 2012).  Synovitis is inflammation of the synovial 
lining which occurs after a joint injury and is also a contributor to the development of 
OA early on but is not as severe as seen in RA (Loeser et al., 2012).  In addition, for 
those with knee OA, pathological changes in the menisci and ligaments contribute to 
the development of OA and occur from disruption of the extracellular matrix as well 
as calcification of the meniscus and the articular cartilage  (Loeser et al., 2012; Molloy 
& McCarthy, 2006).   
There are also three ways OA can be classified including radiographic OA, 
symptomatic OA, or clinical OA (Neogi & Zhang, 2013; Zhang & Jordan, 2010).   
Radiographic OA is based on a radiograph grading scale (Kellgren-Lawrence grading 
scale) that assesses osteophyte presence, deformities, joint space narrowing, cysts, and 
sclerosis.  The system uses five levels (0-4) to classify the severity of the radiographic 
OA and is used to identify OA at the hands, hips, and the knee (Kellgren & Lawrence, 
1957; Neogi & Zhang, 2013; Zhang & Jordan, 2010).  Symptomatic OA differs 
slightly from radiographic OA in that symptomatic OA includes frequent pain, 
stiffness of the joint, and aching with radiographic OA.  The number of individuals 
with symptomatic OA is therefore often lower since characteristics of both 
symptomatic OA and radiographic RA must be present (Lawrence et al., 2008; Neogi 
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& Zhang, 2013; Zhang & Jordan, 2010).  In addition, clinical OA is diagnosed based 
on the results from a physical examination as well as the assessment of symptoms 
(Lawrence et al., 2008).  OA is often diagnosed via a physical examination, 
radiography, lab assessments, as well as reviewing the symptoms presented (Centers 
for Disease Control and Prevention (CDC), 2017b; Lawrence et al., 2008).   
Rheumatoid arthritis is another form of arthritis that also includes a synovitis 
component similar to that of OA, but is more severe (Araki & Mimura, 2016; 
Firestein, 2003; Loeser et al., 2012).  It is a multifactorial disease that has a 
complicated etiology but is includes a combination of environmental factors, genetics, 
as well as epigenetics (Araki & Mimura, 2016; Gibofsky, 2014).   Rheumatoid 
arthritis is a chronic inflammatory autoimmune disease that is characterized by 
inflammation of the synovial lining with a progressive destruction of the affected 
joints that leads to pain and disability (Araki & Mimura, 2016; Gibofsky, 2014).  
Normally, the synovial lining is only 2-3 cells thick but in RA, the lining becomes 10-
15 cells thick due to synovial fibroblasts and synovial macrophages causing 
hyperplasia.  Rheumatoid arthritis synovial fibroblasts (RASF) secrete cytokines and 
chemokines, which contribute to inflammation.  In addition, a pannus, which is 
aggressive tissue formed by RASFs and macrophages, degrades articular cartilage and 
the subchondral bone within the joint (Araki & Mimura, 2016; Firestein, 2003).  Also, 
RA commonly affects the feet and hands small diarthrodial joints (Firestein, 2003).  
All of these factors contribute to the development of RA and the worsening of 
symptoms.  
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Fibromyalgia (FM) is another common form of arthritis found in mainly older 
adults, specifically women.  It is characterized by widespread pain throughout the 
body, which causes tenderness (Lawrence et al., 2008; Panton et al., 2006; Wolfe, 
Ross, Anderson, Russell, & Hebert, 1995).  Symptoms of FM include pain when 
pressure is applied to various tender points, stiffness, as well as mental impairments 
(i.e. anxiety, mental fogginess) (Panton et al., 2006).  Individuals are diagnosed with 
FM if they have widespread pain for at least three months in at least three out of four 
body quadrants.  In addition, they must have localized pain in at least eleven of 
eighteen tender points or at muscle-tendon junctions (Wolfe et al., 1990).  
Gout is another common form of arthritis that is prevalent in older adults 
(typically men) and is characterized by inflammation that occurs from monosodium 
urate monohydrate crystals that undergo phagocytosis.  This causes elevated levels of 
uric acid in the blood leading to hyperuricemia, which is defined as serum uric acid 
levels surpassing urate blood solubility (>6.8 mg/dl) (Burke et al., 2015; De Avila 
Fernandes et al., 2017; Lawrence et al., 2008; Wertheimer, Morlock, & Becker, 2013).  
Uric acid concentrations that exceed blood solubility levels lead to the formation of 
crystals, which deposit in fibrous tissues that create a gouty tophus and in turn 
ultimately lead to inflammation (Wertheimer et al., 2013).  The gouty tophus can 
cause damage to skin, bones, tendons, bursas, and organs.  Gout also occurs in flares 
or episodes and leads to disability and pain and can be characterized into four phases 
as well (Burke et al., 2015; Centers for Disease Control and Prevention (CDC), 2016b; 
Wertheimer et al., 2013).  These phases include asymptomatic tissue deposition, acute 
flare episodes, intercritical segments post flare, and chronic gout.  During 
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asymptomatic tissue deposition, there are no symptoms of gout but the individual does 
have hyperuricemia and crystals begin depositing into tissues.  During the acute flares, 
the crystals cause joint inflammation. Typically, the lower extremities are affected first 
and inflammation is commonly seen in the metatarsophalangeal joint.  Post flare, gout 
enters an inactive phase despite the continuing deposition of crystals from 
hyperuricemia.  Finally, chronic gout is accompanied by pain, aches, and the presence 
of tophi (Centers for Disease Control and Prevention (CDC), 2016b).  Gout is 
typically diagnosed by clinical criteria and by examining the synovial fluid for 
monosodium urate crystals via various techniques  (Centers for Disease Control and 
Prevention (CDC), 2016b; De Avila Fernandes et al., 2017).  
There are many other forms of arthritis including polymyalgia rheumatica 
(PMR) and its sister disease giant cell (temporal) arteritis (GCA) (Cutolo, Cimmino, & 
Sulli, 2009; Lawrence et al., 2008).  Polymyalgia rheumatica is another form of 
arthritis that occurs mainly in those age ≥ 50 years and is characterized by acute 
musculoskeletal inflammation (Cutolo et al., 2009; Lawrence et al., 2008).  It causes 
morning stiffness and aches in the pelvic girdle, the shoulder joint, and neck (Cutolo et 
al., 2009; Gonzalez-Gay, 2004).  GCA, which closely related to PMR, also occurs in 
the older population but causes vasculinitis in the cranial arteries causes symptoms 
such as including visual disturbances and headaches.  GCA can also cause limb 
claudication as well as polymyalgia (Dejaco, Duftner, Buttgereit, Matteson, & 
Dasgupta, 2016; Gonzalez-Gay, 2004).  Overall, arthritis is known to limit 
functionality and lead to disability (Hootman et al., 2012; Song et al., 2006).  In a 
cross sectional analysis using a cohort from the Cardiovascular Health Study, 49% of 
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the participants (n=5201, age ≥65 years) stated that arthritis and other musculoskeletal 
diseases were the main cause of their inability to perform physical functioning 
activities (Ettinger et al., 1994).  Other studies have shown similar results as well 
(Hochberg, Kasper, Williamson, Skinner, & Fried, 1995; Song et al., 2006).  
A longitudinal study that evaluated how arthritis affects disability in older U.S. 
adults (n=7,758, age ≥ 65 years) used participants from the Health and Retirement 
Study (1998-2000).  The participants had to have no ADL disability at the baseline 
measurement and included participants with and without arthritis.  At baseline, 
arthritis was assessed via self-report.  Disability was assessed after two year follow up 
period and was based on participants’ self-reported ability to perform specific ADL 
tasks.  That study used a multiple logistic regression analysis to assess disability 
presence based on arthritis status at baseline.  It was found that compared to those 
participants without arthritis, those with arthritis had a higher two year incident ADL 
disability rate (9.3% versus 4.5%) and an odds ratio (OR) of 2.16 (95% CI:1.80-2.60).  
In addition, the incident rate for disability for women with arthritis increased by 2.2 
times when compared to those without arthritis (10.7% versus 5.1%), and was higher 
than the incident rate of disability for men with and without arthritis (6.8% versus 
3.9%) (Song et al., 2006).  Therefore, since arthritis leads to disability, it is important 
that methods and techniques to predict incident disability are available for various 
areas of the body that are affected.  
Arthritis and Grip Strength 
Various forms of arthritis have been evaluated on their effect on grip strength 
including the most common forms (OA, RA, FM, gout) (Bagis et al., 2003; Burke et 
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al., 2015; Cardoso Fde et al., 2011; Dedeoğlu et al., 2013; Huang et al., 2013; 
Kemmler et al., 2015; Koca et al., 2016; Panton et al., 2006).  In a case-control study 
conducted by Panton, et al. (2006), that study evaluated how FM affected muscular 
strength and physical functioning.  That study compared 29 women (mean 
age=46.0±7.0 years) to 12 age and weight matched women who did not have FM 
(mean age=44.0±8.0 years) and additionally to 38 healthy older women (mean 
age=71.0 ± 7.0 years).  To assess lower body muscular strength, peak isokinetic knee 
extension and flexion torque were measured using a Biodex Isokinetic Machine.  
While to assess upper body muscular strength a hand grip dynamometer was used.  
Physical functioning was assessed using the Continuous Scale-Physical Function 
Performance Test (CS-PFP).  The CS-PFP test uses sixteen activities and assess them 
based on time, distance, and weight.  To measure FM weekly, a fibromyalgia impact 
questionnaire (FIQ) was given to those with FM.  In addition, the number and 
sensitivity of tender points was assessed for those with FM.  That study found that 
there was no significant difference between the women with and without FM in 
regards to grip strength, but the older women had significantly lower grip strength 
scores when compared to the two other groups (p≤0.025).  However, the FM group 
and older women group had significantly lower scores for isokinetic knee extension 
and flexion when compared to the control group (p≤0.025).  That study displayed how 
women with FM have decreased lower body muscular strength but did not differ with 
the controls for upper body strength.  Although FM is a form of arthritis, it may not 
affect grip strength scores because tender points for those with FM are generally in the 
shoulder and neck regions (Panton et al., 2006).  In addition, the closest tender point to 
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the hand that is assessed in those with FM is the forearm (Wolfe et al., 1990).  
However, although FM does not affect grip strength scores, other forms of arthritis 
may.  
In a prospective cohort study that assessed gout and hyperuricemia in older 
adults (≥65 years) and its effect on physical function, similar results in regards to FM 
and grip strength were found.  That study used 5,819 participants (mean age=75.5 
years) with and without gout and hyperuricemia that are part of the Atherosclerosis 
Risk in Communities Study.  That study had five examination periods between 1987 
and 2013 and participants were also contacted annually for a follow-up.  Gout was 
assessed via self-reported, physician diagnosis during visit four or during the annual 
follow-up contact period.  Upper extremity function was assessed using a hand grip 
strength test via a hand grip dynamometer.  Lower extremity function was also 
assessed via the short physical performance battery assessment (SPPB).  The SPPB 
encompasses assessments in balance, gait speed, and repeated chair stands. In 
addition, that study used prevalence ratios (PR) to assess if gout or hyperuricemia 
were associated with poor physical function.  That study found that when after 
adjusting for potential confounders, low grip strength was not significantly affected by 
gout status (PR=1.04, 95% CI:0.92-1.18, P=0.49).  In addition, after adjusting for 
potential confounders, low grip strength was not significantly affected by 
hyperuricemia status as well (PR=0.98, 95% CI:0.89-1.07, P=0.60).  However, SPPB 
was affected by both gout (PR=1.18, 95% CI:1.07-1.32, P=0.002) and hyperuricemia 
(PR=1.09, 95% CI:1.00-1.19, P=0.048).  Therefore, that study concluded that lower 
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extremity physical functioning is poorer in those with gout and hyperuricemia but not 
for grip strength (Burke et al., 2015).    
Although, that study did not show grip strength scores being affected by gout 
status, another study conducted by Huang, C, et al. (2013), showed the opposite.  They 
found that participants with hyperuricemia (associated with gout) had lower grip 
strength scores than those without hyperuricemia (40.3 kg, 95% CI:39.2-41.3 kg 
versus 41.9kg, 95% CI:41.3-42.5 kg, P=0.01) and concluded that hyperuricemia is 
associated with poor muscle strength.  However, that study only used male 
participants and could have affected their results since hyperuricemia and gout are 
more prevalent in males.  In addition that study used a cross-sectional design and a 
study that uses a prospective design needs to be executed to assess the causality of the 
two variables (Huang et al., 2013).  Other studies that have used female participants 
have seen similar results as well  (Cardoso Fde et al., 2011).  Aside from gout and FM, 
other forms of arthritis may affect grip strength. 
 Unlike gout, which commonly affects the metatarsophalangeal joint (Centers 
for Disease Control and Prevention (CDC), 2016b) and FM, which leads to 
widespread pain  (Lawrence et al., 2008; Panton et al., 2006; Wolfe et al., 1995) , RA 
commonly affects the joints of the hand  (Firestein, 2003).  A cross sectional study that 
assessed RA in the hands for its effect on grip strength and pinch strength, as well as 
disease activity, hand functionality, disability, and pain, used 78 female and 24 male 
participants (mean age=52.83±10.50 years).  Hand grip strength was measured using a 
hand-held dynamometer and pinch strength was measured using a hydraulic pinch 
gauge.  Disease activity was assessed using the Disease Activity Score 28 joints (DAS 
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28).  Hand functionality was assessed using the Duroz Hand Index (DHI) and the 
Signals of the Functional Impairment (SOFI) index.  Disability level was assessed 
using the Health Assessment Questionnaire (HAQ) and pain was measured using the 
Visual Analog Scale (VAS).  Articular damage was also assessed using the 
Rheumatoid Arthritis Articular Damage score (RAAD) as well as the Modified Sharp 
Score (MSS).  That study found that the grip strength and pinch strength scores were 
significantly negatively correlated with DAS 28, HAQ, SOFI index, DHI, RAAD 
scores, VAS, MSS, and disease duration (p<0.001).  Therefore in individuals with RA, 
grip strength and pinch strength are decreased and are affected by many aspects of RA 
.  Although this study showed that RA affects grip strength scores, it does not address 
the most common form of arthritis, OA, and also used both men and women 
(Dedeoğlu et al., 2013).  
Similar to RA, OA also affects the joints of the hand and has led to decreased 
grip strength scores (Bagis et al., 2003; Kemmler et al., 2015; Neogi & Zhang, 2013).  
In a case-control study that used postmenopausal women, that study evaluated how 
OA affected hand function and used a grip strength test as a measure.  That study 
included 100 women who had OA (mean age=61.47±8.21 years) and 70 healthy 
women (mean age=60.47±7.54 years) who acted as controls.  The women were 
assessed on grip strength, pinch strength, hand function via survey, and on their OA 
symptoms including pain, nodules, and tenderness.  Grip strength was measured using 
a Jamar hand grip dynamometer and pinch strength was measured using a hydraulic 
pinch gage.  Hand function was assessed using the Dreiser’s functional index and pain 
was assessed using a visual analog scale.  The KL scale was used to assess and grade 
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radiographs (hand OA grade 2 or higher) (Kellgren & Lawrence, 1957)  and joints 
were assessed via palpation.  That study found that grip and pinch strength scores were 
significantly lower (p<0.05) in the participants with OA compared to those who were 
healthy while the Dreiser’s Functional Index scores were significantly higher among 
those with OA compared to the healthy participants (p<0.001).  In addition, those who 
were considered with grade 4 OA had significantly lower grip and pinch strength 
scores than those in the control group or grade 2 OA or grade 3 OA groups (p<0.05).  
Participants who had Herberden and Bouchard nodules had lower grip (p=0.039, 
p=0.050) and pinch strength (p=0.050, p=0.015) scores compared to the healthy 
counterparts as well.  Also, participants were more likely to have significantly 
decreased hand function with increased pain and tenderness (p<0.05).  That study 
concluded that OA significantly impairs hand function as well as grip and pinch 
strength (Bagis et al., 2003).  
Arthritis and Sarcopenia  
 Numerous studies have evaluated the effect of different forms of arthritis on 
grip strength scores but did not assess arthritis to sarcopenia status.  A study that did 
assess FM in relation to sarcopenia status was conducted by Koca et al. (2016), using a 
cross-sectional, case controlled design.  That study used women between the ages of 
18-60 years and included 82 participants with FM (mean age=40.7±2.0 years) and 38 
healthy control female participants (mean age=38.8±2.8 years).  Participants with FM 
were evaluated with the FIQ to evaluate each participant’s severity of FM.  In 
addition, these participants completed a visual analog scale questionnaire to quantify 
their level of pain as well as other questionnaires.  To assess sarcopenia status, 
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muscular strength, body composition, and a physical functioning assessment.  
Muscular strength was assessed using a hand grip dynamometer for three trials with 
the average score being recorded.  That study used a cut point of <22.5kg.  Body 
composition was assessed using BIA and height and weight were assessed to calculate 
BMI.  A skeletal muscle index (SMI) (appendicular skeletal muscle mass/height2) of 
<6.75 kg/m2 was used and was based of the reference data by the EWGSOP (Cruz-
Jentoft et al., 2010).  Physical functioning was assessed using a six meter gait speed 
test and a cutoff of ≤0.8m/s was used.  Participants were also classified as 
presarcopenic, sarcopenic, or severely sarcopenic based on the EWGSOP staging 
(Cruz-Jentoft et al., 2010).  That study found that overall, there were nine participants 
with sarcopenia and four with presarcopenia in the FM group and two participants 
with presarcopenia in the control group as well.  Also, grip strength scores and gait 
speed scores were significantly lower in the FM group when compared to the control 
group (p=0.023, p<0.001 respectively).  For body composition there was no 
significant difference between the FM participants and the control participants (Koca 
et al., 2016).  However, this study did not address if sarcopenia status was affected by 
the presence of FM, rather it addressed if components of sarcopenia could be affected 
by FM.  Also, that study did not use older women but used a wider age range and 
younger population of women.  
 Another study that assessed arthritis to sarcopenia status was conducted by 
Kemmler, et al. (2015).  A cross-sectional study was used to assess data from the 
FORMosa Project (Bavarian Research Association – Sarcopenia and Osteoporosis) to 
evaluate the prevalence of sarcopenia in people with and without OA.  That study took 
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place in Erlangen, Germany and used only Caucasian women (n=1,325) who were age 
70 years and older (mean age=76.4±4.9 years).  There were 232 participants who had 
OA that was confirmed by questionnaires and a physician.  In regards to sarcopenia 
status, there were 21 out of 232 women (9.1%) with OA who were classified as 
sarcopenic while only 38 women (3.5%) out of 1,502 who did not have OA were 
classified as sarcopenic.  In addition, significantly more OA participants had a grip 
strength less than 20 kg when compared to the non-arthritic counterparts (29.9% and 
16.6% respectively) (p=0.001).  The OA participants were also significantly slower 
(p=0.001) and had more participants with low lean mass than the non-arthritic 
counterparts (p=0.327).  However, that study only evaluated the influence of OA on 
sarcopenia status as an exploratory aim and only asked about OA in the knee and hip 
and not the hands (Kemmler et al., 2015).  To address the current gap in the literature, 
future studies should address how sarcopenia status may be influenced by various 
forms of arthritis and their impact on the components of sarcopenia criteria including 
muscular strength, physical functioning, and body composition.   
Conclusion 
 While other studies have shown that various forms of arthritis affect grip 
strength, others have reported conflicting results.  Grip strength is also a key aspect of 
many national and international organizations working definitions for sarcopenia.  
Therefore, it is possible that grip strength could impact sarcopenia status when hand 
arthritis is present and potentially misclassify people.  This may be more true among 
older women since arthritis is prevalent in that population and they experience faster 
declines in muscular strength than men.  No study has evaluated the effect of hand 
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arthritis on sarcopenia classification in older women based on current working 
definitions.  Future studies addressing hand arthritis to overall muscular strength in 
older women with symptoms of sarcopenia are needed as well.  Components of 
arthritis such as severity, pain, type, and joints affected should be considered when 
addressing arthritis to sarcopenia criteria and should be evaluated to see if those 
variables would affect sarcopenia status.  
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APPENDIX B: Phone Screen Interview 
 
URI Resistance Exercise Study to Reclaim Lean Muscle and Strength (URI 
RESTORE ME Project) 
Data Sheet for Detailed Subject Telephone Interview 
 
 Brief Explanation of Study 
 Permission to Conduct Interview?      ______Yes   _______No    
Comment:___________________________________________________________ 
 
Name:  Dr./Ms./Mrs.________________________________________________ 
Address: ________________________________________________________ 
     ________________________________________________________ 
Phone #:_________________________________________________________ 
E-Mail:___________________________________________________________ 
Best Way and Time to Contact:________________________________________ 
• Time Commitment – Available 
   ____Yes    ____No       Wants to be contacted after ________ (Date) 
Comment:___________________________________________________________ 
 
• Proximity to URI 
Length of commute: ______ miles  or  ______ minutes 
Within reasonable commute_____       Willing to make unreasonable 
commute______ 
Too far to commute______ 
• Age 
Age: _____ yrs  Date of Birth:  _____/_____/_____ 
          MM   DD  YY 
Approximate Height:  ___________ Approximate Weight: ___________  
 BMI: ____________ 
• Race 
  ___ American Indian or Alaskan Native 
 ___ Asian or Pacific Islander 
   ___ Black, not of Hispanic origin 
   ___ Hispanic 
   ___ White, not of Hispanic origin 
   ___ Other/Unknown   
• Highest level of education completed 
 ___ Less than high school 
 ___ High school or GED 
 ___ Some college 
 ___ Two-year college degree (e.g. Associates) 
 ___ Four-year college degree (e.g. B.S., B.A.) 
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___ Masters degree 
___ Doctoral degree 
 ___ Professional degree (e.g. M.D., J.D.) 
 ___ Other (please specify) ________________________________________ 
• Have you attained menopause?  Yes ______ No_______ 
If Yes, for how long? _____________________ 
• Smoking  
Always Non-Smoker_______    Non-Smoker for ___________    
Smoker________ 
 
• Physical Activity 
      Participates in regular (>1x/wk for past 3 months) exercise?      ____Yes     
_____No  
     If yes, describe in detail (e.g. frequency, intensity, duration, mode) 
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
_____________________________________________ 
     Describe other non-structured physical activity (e.g. leisure time, gardening, 
occupational, or other) 
____________________________________________________________________
____________________________________________________________________
______________________________ 
• Cardiovascular (heart, blood, or blood vessel) conditions? 
____No    ____Yes (Record on Medical History/Treatment Form) 
Comments:_____________________________________________________ 
  
 ______________________________________________________________ 
 
• Respiratory Conditions? 
____No    ____Yes (Record on Medical History/Treatment Form) 
Comments:_____________________________________________________ 
   
 ______________________________________________________________ 
 
• Osteoarthritis/Degenerative Arthritis 
 ___No     ___Yes 
If yes, how long and what was the 
severity______________________________ 
____________________________________________________________ 
 
• High Blood Pressure 
  No_____  
Yes_____ Controlled (Record High BP and Treatment on Medical 
History/Treatment Form)  
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Yes_____ Uncontrolled 
Comments:________________________________________________________
_________________________________________________________________ 
 
• Orthopedic conditions (knee, neck, or other back pain) 
___No      ___Yes 
If yes, describe in detail including severity 
______________________________________________________________
______________________________________________________________
______________________________ 
 
 
• Diabetes 
 _____No  
_____Yes – Type 2. If type 2, taking insulin now? 
_______________________ 
_____Yes – Type 1 (Insulin Dependent) 
 Comments:_____________________________________________________ 
 
       ________________________________________________________________ 
 
• Any major surgeries as an adult? 
___No      ___Yes 
If yes, what type (e.g. surgeries of the joints, heart surgeries, angioplasty, 
bypass surgery, pacemakers, etc.) and date(s) 
______________________________________________________________
______________________________________________________________
______________________________________________________________
_____________________________________________ 
 
• Other Medical Conditions (especially those that would make exercise difficult 
or unsafe) 
 _____No  
_____Yes (Record on Medical History/Treatment Form)  
 Comments:_____________________________________________________ 
 
____________________________________________________________________ 
 
• Medication Info – See last page 
 _____No  
_____Yes (Record on Medical History/Treatment Form)  
 Comments:___________________________________________________  
            
____________________________________________________________________ 
 
• Personal Physician Info 
 Name of Physician:  
______________________________________________________ 
 Specialty of Physician: 
____________________________________________________ 
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Phone Number:__________________________________________  
 Fax Number: 
____________________________________________________________ 
 Address (if phone and fax unknown): 
________________________________________ 
______________________________________________________________ 
______________________________________________________________  
• Summary 
Interviewer Printed Name: ______________________________________ 
        
Interviewer Signature:       ______________________________________ 
 
 Questions/Comments:_______________________________________ 
  
______________________________________________________________ 
Reviewer Initials: ______  
 
 _____Appears to Qualify   _____Need More Information  
_____Needs Drs. Delmonico, Hatfield, Xu, or Lofgren to review  
_____ Not Qualified 
  
Questions/ 
Comments:___________________________________________________________
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Medication/Dietary Supplement Form 
 
 
 
 
 
 
Name  
Date  
Condition/Reason Severity Name of 
Medication/Supplement 
Date 
started 
Dose 
(mg/times/day) 
Expected 
to 
Change? 
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Initial____ Date_____ Page 2 of 6 
 
your hands. This will tell us in less than one minute how much arm and leg muscle you have. 
This device uses a very low electrical current in order to estimate muscle and fat mass on your 
body.  This test only takes about one minute to complete but is a valid and reliable measure of 
body composition with very few risks.  The walking test simply requires you to walk four 
meters (about 15 feet) at your normal walking pace. The hand grip strength test only takes a 
couple of minutes and you will be asked to squeeze a device two times with both hands 
(separately) as hard as you can.  Your height and weight will also be measured at this visit.  If 
you meet the criteria that identify you as having sarcopenia, then you will be invited to take 
part in the project.  If you do not meet these criteria, we will provide you with information 
about your muscle mass and physical functioning, along with information about how you can 
maintain or improve these health aspects on your own.  
 PHASE 2:  If you are identified as having sarcopenia, then you will be invited to take part 
in the research trial.  Preliminary testing (four visits of ~ 1–1.5 hours per visit) will be 
necessary.  In addition to a repeat of some of the measures in Phase 1, your , waist and hip 
girths will be measured and you will be asked to complete some tasks to measure your ability 
to carry out normal daily activities at the Independence Square building.  These tasks include a 
usual pace 400 meter (~ ¼ mile) walk, rising from a chair, standing balance tests, and short 
walks.  Any risk of injury during the completion of these tasks will be minimized by having all 
sessions supervised by an exercise physiologist qualified to direct this type of testing.  In 
addition, you will be asked to complete several health questionnaires. These include sleep 
quality, general health, food intake, a dietary screening tool, a balance survey, and physical 
activity habits.   
You understand that your percent body fat and bone density will be performed using dual 
energy x-ray absorptiometry (DXA) located in room 129 of the Independence Square building.  
This will require you to lay on a table a wearing hospital scrubs for about 20 minutes for the 
entire procedure.  A licensed radiology technician will perform the DXA scans.  There is no 
cost to you or your insurance for these scans. 
The flexibility of your leg muscles will be tested by using a simple test that requires you to 
attempt to touch your toes while seated.  You also understand that strength assessments will be 
performed on machines or devices that measure how much force and how fast you can exert 
force through a typical range of leg, back, chest and knee extension motion.  Leg strength 
testing will be performed by measuring the maximal amount of force that you can move 
through the full range of an exercise. You may experience some temporary muscle soreness as 
a result of the testing sessions.  There is also a risk of muscle soreness or skeletal injury from 
strength and testing as well as from the exercise training.  The investigators of this study will 
use procedures designed to minimize this risk.  
A blood test will be done that will include two blood draws to analyze blood sugar, lipids 
(fats), and other blood proteins.  You understand that there is a risk of bruising, pain, and in 
rare cases, infection or fainting as a result of blood sampling.  However, these risks to you will 
be minimized by allowing only qualified people to draw your blood.  Your blood pressure will 
also be assessed during this first phase. 
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At the end of the Phase 2 (testing), you will be randomly assigned (like a flip of a coin) to 
either a resistance training group or a general physical activity group for Phase 3.  You 
understand that you are not allowed to choose which group you will be assigned.    
PHASE 3:  INTERVENTION 
Resistance Training Sessions (Resistance Training Group) 
If you are randomized to the resistance training exercise group, you will also be asked to 
participate in three (3) supervised exercise sessions per week (~ 45 minutes per visit) for the 
12-week intervention in the Independence Square building, room 190.  During each resistance 
training session you will be asked to exercise on machines or free weights that offer resistance 
against extending and flexing your arms, legs, and trunk region.  All sessions will start with a 
resting blood pressure and a brief warm-up. The first several resistance training sessions will 
begin with lighter resistances to get you used to the resistance training program.  The 
resistances will be gradually increased based on individual progress.  The resistance will 
always be adjusted so that you are exercising at near maximal effort.  You will be able to 
provide feedback using standardized pain and discomfort rating scales. Your overall progress 
will be monitored by an exercise specialist so that you are able to tolerate the exercise.  Each 
session will end with a cool-down and a final blood pressure measurement.  No special clothing 
is required, but you should dress in clothing that is comfortable and that allows you to move 
freely.  You will also be instructed to stop exercising immediately if you experience chest pain, 
muscle injuries, or any other unexpected symptoms.  Although you will always have 
supervision when doing exercise training during this study, if you ever experience chest pain 
while exercising at other times, you should immediately call 911 to seek emergency care and 
notify your primary care physician.  If you have any problems or injuries, you should also 
notify a member of the study team.  Study team members and their phone numbers are noted on 
the first page of this consent form. 
General Physical Activity Sessions (Active Control Group) 
 If you are assigned to the active control group, you will also be asked to participate in three 
(3) supervised exercise sessions per week (~ 45 minutes per visit) for the 12-week intervention 
in the Independence Square building, room 190.  During each general physical activity session, 
you will engage in individual and group exercise sessions to increase your overall weekly 
physical activity. Activity sessions will vary but will include activities recommended by the 
American College of Sports Medicine for adults 65 years and older. Some of these activities 
may include walking, Tai Chi, light calisthenics, and stretching.  All sessions will start with a 
resting blood pressure and a brief warm-up. The first several exercise sessions will begin with 
very light activities to get you used to the training program.  The difficulty of the exercises will 
be gradually increased based on individual progress.  You will be able to provide feedback 
using standardized pain and discomfort rating scales. Your overall progress will be monitored 
by an exercise specialist so that you are able to tolerate the exercise.  Each session will end 
with a cool-down and a final blood pressure measurement.  No special clothing is required, but 
you should dress in clothing that is comfortable and that allows you to move freely.  You will 
also be instructed to stop exercising immediately if you experience chest pain, muscle injuries, 
or any other unexpected symptoms.  Although you will always have supervision when doing 
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exercise training during this study, if you ever experience chest pain while exercising at other 
times, you should immediately call 911 to seek emergency care and notify your primary care 
physician.  If you have any problems or injuries, you should also notify a member of the study 
team.  Study team members and their phone numbers are noted on the first page of this consent 
form. 
 PHASE 4:  Phase 4 will be a repeat of previously taken measures at the mid-point (week 6) 
and at the end (after week 12) of the 12-week exercise intervention.   
 
 PHASE 5:  Phase 5 (the final phase) of the project will be six month follow-up testing 
session after Phase 4. You do not need to do any special activity or diet during this period.  
 
Risks or discomfort: 
 You understand that it is possible that heart or blood vessel problems could arise during 
your participation in the testing or training involved in this study.  Although highly unusual, it 
is possible that these problems could lead to a heart attack, stroke or even death.  Therefore, 
prior evaluation and written clearance with a signature from your personal physician is 
strongly encouraged for you to participate in this study.  You also understand that it is possible 
that these risks will not be eliminated completely, even with a medical evaluation prior to 
participation in the study.  However, the investigators believe the risk of harm from study 
participation is relatively small and that the benefits of the study will likely outweigh any 
potential risks.  Additionally, you understand that with the testing described above, resistance 
training and exercise in general there is a risk of muscle soreness or other muscle injury as well 
as skeletal injury.  Because exercise in this study does require some degree of balance, there is 
also a risk of falling associated with exercise.  However, the investigators will take precautions 
in order to reduce the likelihood that these adverse events will occur. 
You understand that there will also be a very low total radiation dose for the DXA scans 
(~39 millirem), which is about one-fifth the radiation dose of a standard chest X-ray and is 
well below the maximal annual radiation dose (5 rems) allowed for exposure in the workplace.  
Naturally occurring radiation (cosmic radiation, radon gas, etc.) gives each person a whole 
body radiation dose of about 300 millirems per year.  Therefore, the total dose of radiation 
exposure due to DXA is considered low.  The major risk from high radiation exposure is 
passing on damaged genes (genetic mutations) to offspring.  Therefore, this risk is of primarily 
a concern for those who are of childbearing age. 
In case there is any injury to the subject: 
In the event of physical injury resulting from participation in this study, upon your consent, 
emergency treatment will be available at South County Hospital with the understanding that 
any injury that required medical attention becomes your financial responsibility.  You 
understand that URI  will not provide any medical or hospitalization insurance coverage for 
participants in this research study, nor will they provide compensation for any injury sustained 
as a result of this research study, except as required by law. 
 You understand that if you are injured while participating in this research project as a 
result of negligence of all state employees who are involved in this research project, you may 
be able to be compensated for your injuries in accordance with the requirements of the Federal 
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Tort Claims Act.  If you are a federal employee acting within the scope of your employment, 
you may be entitled to benefits in accordance with the Federal Employees Compensation Act.  
Confidentiality: 
All information collected in this study is confidential, and your name will not be identified 
and linked to any electronic study data at any time to anyone other than the principal 
investigators of the study.  Your data will be coded with an ID number only, which will be 
linked back to you only by the principal investigators of the study.  Your part in this study is 
confidential within legal limits.  The researchers and the University of Rhode Island will 
protect your privacy, unless they are required by law to report information to city, state or 
federal authorities, or to give information to a court of law.  Otherwise, none of the information 
will identify you by name.  All study data, including this consent form, will be locked in a file 
cabinet and also stored in a study computer with a password secured in our study office 
(Independence Square building, Suite P, room 119).  
Benefits of this study: 
 You understand that this study is not designed to help you personally, but may help the 
investigators better understand which interventions are the most effective in helping women 
who have sarcopenia improve their muscle mass and physical function.  However, because of 
what is already known regarding the effects of resistance training and exercise in general, it is 
likely that you will notice some benefits.  These potential benefits include improved strength, 
mobility and blood pressure. 
For your participation in the study and after the study is completed, you will receive, free 
of charge, information about your blood pressure, blood test results, body composition, muscle 
strength, and physical function.   
Decision to quit at any time: 
 You understand that is your decision and your decision alone whether or not you consent 
to participate in this study.  You are free to ask questions about this study before you decide 
whether or not to consent to participate in it.  Also, if you consent to participate in the study 
you are free to withdraw from participation at any time without penalty or coercion, or without 
any requirement that you provide an explanation to anyone of your decision to withdraw.  You 
or your insurance company will not be charged for the classes or training sessions. 
Rights and Complaints: 
If you are not satisfied with the way this study is performed, you may discuss your 
complaints with the principal investigators, Drs. Matthew Delmonico at (401) 874-5440, Disa 
Hatfield at (401) 874-5183, Ingrid Lofgren at (401) 874-5869, or Furong Xu (401) 874-2412 
(anonymously, if you choose).  In addition, if this study causes you any injury or if you have 
questions about your rights as a research subject you may contact the office of the Vice 
President for the Division of Research and Economic Development, Carlotti Administration 
Building, 2nd Floor, 75 Lower College Road, Suite 2, University of Rhode Island, Kingston, 
Rhode Island; telephone:  (401) 874-4576. 
Alternatives to study participation:  If you choose not to participate in this study, you are 
encouraged to discuss with your physician about exercise strategies. 
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 You have read and understand the above information in the Consent Form and have been 
given adequate opportunity to ask the investigators any questions you have about the study.  
Your questions, if any, have been answered by the investigators to your satisfaction.  Your 
signature on this form means that you understand the information and you agree to voluntarily 
participate in this study.  
 
________________________  ________________________ 
Signature of Participant    Signature of Researcher 
 
_________________________  ________________________ 
Typed/printed Name    Typed/printed name 
 
__________________________  _______________________ 
Date        Date 
 
 
By signing again below you give permission for the investigators to store and use your blood 
samples for future research only related to the study objectives. 
 
________________________  ________________________ 
Signature of Participant    Signature of Researcher 
 
_________________________  ________________________ 
Typed/printed Name    Typed/printed name 
 
__________________________  _______________________ 
Date        Date 
 
 
Please sign both consent forms, keeping one for you. 
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APPENDIX F: Orientation/Screening Checklist and Data Collection Sheet 
 
 
URI	RESTORE	ME	Study:		Orientation	Checklist/Screening	
Name:																																																																	Date:					
Participant	ID:																																																																																																												
																																																																																																																																																																																																																																																																																																																																							
CHECKLIST																																																																																																																																		
	 	 	 							Item	 	 												Yes	 	 														No																																				Initial	
Consent	Teach	Back	Complete	 	 				 	
Consent	Form	Signed	 																													/							/2015	 	
Time	of	Last	Meal	 	 	
Hydration	Status	 	 	
Current	Illness	(Sx’s)	 	 	
Recent	Vigorous	Exercise		
(Comments)	
	 	 	
	
SCREENING	INFORMATION																																																																																														 			Initial	
In-Body:	BIA	 	 						 	
Pacemaker	or	Internal	Defibrillator?	 			Yes	 		No	 	
Height:	 Weight:	 BMI:		 	
R	Arm	LM:	 L	Arm	LM:	 R	Leg	LM:	 L	Leg	LM:	 	
	 Total	ALM:	 	
	 	 	
Grip	Strength		 	 	
Dynamometer	Setting:	 Best	Grip	Trial:	 	
Grip	R1:	 Grip	R2:	 Grip	L1:	 Grip	L2:	 	
	 	 	
4m	Gait	Speed	 Time	1:		 Time	2:	 	
Ability	to	Perform	Chair	Stand?	 	 		Yes	 	 			No	 	
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APPENDIX H: Yale Physical Activity Scale Questionnaire 
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APPENDIX I: Dietary Screening Tool
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Appendix G. Dietary Screening Tool 
 
DIRECTIONS: Please check one response to each question that best describes how 
you eat.  
 
How often do you usually eat fruit as a snack?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you usually eat whole grain breads?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you usually eat whole grain cereals?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you usually eat candy or chocolate?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat crackers, pretzels, chips, or popcorn?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat cakes or pies?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week 
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How often do you eat cookies?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat ice cream?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat cold cuts, hot dogs, lunchmeats or deli meats?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat bacon or sausage?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat carrots, sweet potatoes, broccoli, or spinach?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 or more times a week  
 
How often do you eat fruit (not including juice)? Please include fresh, canned or 
frozen fruit.  
____ Never or Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
 
How often do you eat hot or cold breakfast cereal?  
____ Never  
____ Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
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How often do you drink some kind of juice at breakfast?  
____ Never or Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
 
How often do you eat chicken or turkey?  
____ Never or less than once a week  
____ 1 or 2 times a week  
____ More than 3 times a week  
 
How often do you drink a glass of milk?  
____ Never or Less than once a week  
____ 1 or 2 times a week  
____ 3 to 5 times a week  
____ Every day or almost every day  
____ More than once every day  
 
Do you usually add butter or margarine to foods like bread, rolls, or biscuits?  
____ Yes  
____ No  
 
Do you usually add fat (butter, margarine or oil) to potatoes and other 
vegetables?  
____ Yes  
____ No  
 
Do you use gravy (when available) at meals?  
____ Yes  
____ No  
 
Do you usually add sugar or honey to sweeten your coffee or tea?  
____ Yes  
____ No  
 
Do you usually drink wine, beer or other alcoholic beverages?  
____ Yes  
____ No 
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How often do you eat fish or seafood that IS NOT fried?  
____ Never  
____ Less than once a week  
____ Once a week  
____ More than once a week  
 
How many servings of milk, cheese, or yogurt do you usually have each DAY?  
____ None  
____ One  
____ Two or more  
 
How many different vegetable servings do you usually have at your main meal of 
the day?  
____ None  
____ One  
____ Two  
____ Three or more  
 
Which of the following best describes your nutritional supplement use?  
____ I don’t use supplements  
____ I use supplements other than vitamins and mineral  
____ I use a multivitamin/mineral preparation (e.g. Centrum) 
 
 
 
 
 
 
